NYQ·Healthcare·$466M·#139 / 520 in Healthcare
ADCT ADC Therapeutics SA
60SPECULATIVE
CATEGORY BREAKDOWN
GROWTH24
QUALITY60
STABILITY86
VALUATION66
GOVERNANCE49
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+14.9%
24
> 50% strong
Gross Margin
Revenue retained after direct costs
92.9%
100
> 50% strong
Cash Runway
Months of cash at current burn rate
22 months
79
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
-63.0%
100
< 25% strong
Price / Sales
Market cap relative to trailing revenue
5.7x
66
< 3x strong
Rule of 40
Growth rate plus operating margin
-117
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
13.2%
71
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+25.0%
5
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE ADCT WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when ADCT's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.